Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination.
Filippo FagniKatja SchmidtDaniela BohrLarissa Valor-MéndezFabian HartmannKoray TascilarKarin MangerBernhard MangerArnd KleyerDavid SimonGeorg SchettThomas HarrerPublished in: RMD open (2022)